Epkinly (Epcoritamab-Bysp) Patent Expiration, LOE Window & CMS Spending
Epkinly (Epcoritamab-Bysp) by Genmab Us: Biologic BLA (Purple Book Regime), 0 AB generics, $3.8M 2024 CMS Part D & Medicaid spend, and $15,226 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Genmab Us |
| FDA Application & Pathway | B761324 (BLA) |
| Exclusivity / Cliff Horizon | Biologic BLA (Purple Book Regime) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $3.8M |
| 2024 Medicare Part D Spend | $1.2M |
| 2024 Medicaid Spend | $2.6M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($15,226 intro WAC) |